PMID- 20927018
OWN - NLM
STAT- MEDLINE
DCOM- 20110311
LR  - 20161125
IS  - 1824-4785 (Print)
IS  - 1824-4785 (Linking)
VI  - 54
IP  - 5
DP  - 2010 Oct
TI  - Use of PET/CT for staging and radiation therapy planning in patients with 
      non-small cell lung cancer.
PG  - 510-20
AB  - Positron emission tomography (PET) and more recently PET/computed tomography (CT) 
      scanning represent major advances in the imaging of lung cancer and have an 
      especially high impact on the management of patients who are candidates for 
      potentially curative or "radical" radiotherapy (RT). This article reviews the 
      current status of PET and PET/CT for staging patients before RT and considers the 
      use of PET and PET/CT images for target volume definition. The relevant 
      literature on the use of PET for staging lung cancer is reviewed and placed in 
      the context of patients who are candidates for RT. Research that specifically 
      considers the use of PET for RT planning is considered critically and some 
      promising areas for future research are discussed. The available literature is 
      almost exclusively devoted to non small cell lung cancer (NSCLC) with few 
      relevant studies of small cell lung cancer (SCLC). The primary PET 
      radiopharmaceutical shown to have value for staging and RT planning is 
      18F-fluorodeoxyglucose (FDG). In prospective studies where PET imaging was used 
      to stage radical RT candidates, 25-30% of patients were excluded from radical 
      therapy because of PET detected advanced disease. In all studies where 
      "PET-assisted" and conventional target or treatment volumes were compared, there 
      were major differences between PET and conventional volumes. Because PET-assisted 
      staging is proven to be significantly more accurate than conventional staging and 
      because all studies show major differences between PET-assisted and conventional 
      treatment volumes in NSCLC, routine use of PET/CT for RT planning is recommended.
FAU - Mac Manus, M P
AU  - Mac Manus MP
AD  - Department of Radiation Oncology, Peter MacCallum Cancer Institute. East 
      Melbourne, Victoria, Australia. michael.macmanus@petermac.org
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Italy
TA  - Q J Nucl Med Mol Imaging
JT  - The quarterly journal of nuclear medicine and molecular imaging : official 
      publication of the Italian Association of Nuclear Medicine (AIMN) [and] the 
      International Association of Radiopharmacology (IAR), [and] Section of the 
      Society of...
JID - 101213861
SB  - IM
MH  - Carcinoma, Non-Small-Cell Lung/diagnostic imaging/*pathology/*radiotherapy
MH  - Humans
MH  - Lung Neoplasms/diagnostic imaging/*pathology/*radiotherapy
MH  - Neoplasm Staging
MH  - Positron-Emission Tomography/*methods
MH  - Radiotherapy Planning, Computer-Assisted/*methods
MH  - Tomography, X-Ray Computed/*methods
EDAT- 2010/10/12 06:00
MHDA- 2011/03/12 06:00
CRDT- 2010/10/08 06:00
PHST- 2010/10/08 06:00 [entrez]
PHST- 2010/10/12 06:00 [pubmed]
PHST- 2011/03/12 06:00 [medline]
AID - R39102305 [pii]
PST - ppublish
SO  - Q J Nucl Med Mol Imaging. 2010 Oct;54(5):510-20.